Host CD25 +CD4 +Foxp3 + Regulatory T Cells Primed by anti-CD137 mAbs Inhibit Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1, 2012, Pages 44-54

  Kim, Juyang ^a   Kim, Wongyoung ^a   Kim, Hyun J ^b   Park, Sohye ^b   Kim, Hyun A ^b   Jung, Daehee ^b   Choi, Hye Jung ^a   Park, Sang J ^a   Mittler, Robert S ^a   Cho, Hong R ^a   Kwon, Byungsuk ^a,b  

^a Ulsan University College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

CD137; GVHD; Regulatory T cells

Indexed keywords

CD137 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HOST CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MONONUCLEAR CELL; MORBIDITY; MOUSE; NONHUMAN; RAT; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SURVIVAL; T CELL DEPLETION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; ANTIGENS, CD4; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY;

EID: 84855452270     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.09.004     Document Type: Article

References (41)

1. Murphy W.J. Revisiting graft-versus-host disease models of autoimmunity: new insights in immune regulatory processes. JClin Invest 2000, 106:745-747.
2. + T cell priming through invivo ligation of glucocorticoid-induced TNF receptor. JImmunol 2006, 176:5223-5231.
3. + T cell tolerance through invivo ligation of CD40 results in inhibition of chronic graft-versus-host disease and complete donor cell engraftment. JImmunol 2008, 181:7380-7389.
4. Blazar B.R., Lees C.J., Martin P.J., et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. JImmunol 2000, 165:4901-4909.
5. + T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: " natural suppressor" cells. J Immunol 2001, 167:2087-2096.
6. + T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 2004, 104:1565-1573.
7. + regulatory T cells. J Immunol 2004, 173:2428-2434.
8. + T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 2007, 179:7295-7304.
9. Wing K., Yamaguchi T., Sakaguchi S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol 2011, 32:428-433.
10. Krenger W., Cooke K.R., Crawford J.M., et al. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 1996, 62:1278-1285.
11. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., Ferrara J.L. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997, 90:3204-3213.
12. + T cells denotes aregulatory memory phenotype. Am J Transplant 2010, 10:2410-2420.
13. Zhu Y., Zhu G., Luo L., Flies A.S., Chen L. CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 2007, 109:4882-4889.
14. Narazaki H., Zhu Y., Luo L., Zhu G., Chen L. CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood 2010, 115:1941-1948.
15. Sawitzki B., Kingsley C.I., Oliverira V., Karim M., Herber M., Wood K.J. IFN-γ production by alloantigen-reactive regulatory T cells is important for their regulatory function invivo. J Exp Med 2005, 201:1925-1935.
16. Bogdándi E.N., Balogh A., Felgyinszki N., et al. Effects of low-dose radiation on the immune system of mice after total-body irradiation. Radiat Res 2010, 174:480-489.
17. + T cells. Blood 2005, 105:2206-2213.
18. Sun Y., Sun Y., Lin X., et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 2002, 168:1457-1465.
19. Polte T., Foell J., Werner C., et al. CD137-mediated immunotherapy for allergic asthma. J Clin Invest 2006, 116:1025-1036.
20. Seo S.K., Choi J.H., Kim Y.H., et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004, 10:1088-1094.
21. Sun Y., Chen H.M., Subudhi S.K., et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 2002, 8:1405-1413.
22. Foell J., Strahotin S., O'Neil S.P., et al. CD137 costimulatory Tcell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 2003, 111:1505-1518.
23. Kim J., Kim H.J., Park K., et al. Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease. Blood 2007, 110:776-782.
24. Niu L., Strahotin S., Hewes B., et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007, 178:4194-4213.
25. Lee S.W., Salek-Ardakani S., Mittler R.S., Croft M. Hypercostimulation through 4-1BB distorts homeostasis of immune cells. JImmunol 2009, 182:6753-6762.
26. Granucci F., Feau S., Angeli V., Trottein F., Ricciardi-Castagnoli P. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J Immunol 2003, 170:5075-5081.
27. Cheng G., Yu A., Malek T.R. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev 2011, 241:6376.
28. Tang Q., Adams J.Y., Penaranda C., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
29. Boyman O., Kovar M., Rubinstein M.P., Surh C.D., Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006, 311:1924-1927.
30. Létourneau S., van Leeuwen E.M., Krieg C., et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci USA 2010, 107:2171-2176.
31. Webster K.E., Walters S., Kohler R.E., et al. Invivo expansion of Treg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of isletallografts without immunosuppression. J Exp Med 2009, 206:751-760.
32. Grinberg-Bleyer Y., Baeyens A., You S., et al. L-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010, 207:1871-1878.
33. + T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol 2009, 183:51-58.
34. Myers L., Croft M., Kwon B.S., Mittler R.S., Vella A.T. Peptide-specific CD8 T regulatory cells use IFN-γ to elaborate TGF-β-based suppression. J Immunol 2005, 174:7625-7632.
35. Jeon H.J., Choi J.H., Jung I.H., et al. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 2010, 121:1124-1133.
36. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
37. + immunoregulatory T cells suppress polyclonal T cell activation invitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296.
38. + regulatory T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001, 193:1285-1294.
39. + immunoregulatory T cells is antigen nonspecific. J Immunol 2000, 164:183-190.
40. Kim W., Kim J., Jung D., et al. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:306-314.
41. Kwon B. Intervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease. Exp Mol Med 2010, 42:671-683.